Recent developments in the management of severe asthma

Fevipiprant is unlikely to be implemented as a future treatment for severe asthma, while tezepelumab may be a future treatment option for patients with severe asthma with and without eosinophilic inflammation https://bit.ly/3KE1BH4

Detalles Bibliográficos
Autores principales: Meteran, Howraman, Tønnesen, Louise Lindhardt, Sivapalan, Pradeesh, Ingebrigtsen, Truls Sylvan, Jensen, Jens-Ulrik Stæhr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Journal Club
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584584/
https://www.ncbi.nlm.nih.gov/pubmed/36338257
http://dx.doi.org/10.1183/20734735.0178-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584584/
https://www.ncbi.nlm.nih.gov/pubmed/36338257
http://dx.doi.org/10.1183/20734735.0178-2021

Ejemplares similares